Literature DB >> 22386921

The effects of the modulation of the fibronectin-binding capacity of fibrin by thrombin on osteoblast differentiation.

Joung-Hwan Oh1, Hye-Jin Kim, Tae-Il Kim, Jeong-Hwa Baek, Hyun-Mo Ryoo, Kyung Mi Woo.   

Abstract

Fibrin is a natural provisional matrix involved in wound healing and is widely utilized for tissue regeneration. The biological performance of fibrin is largely dependent on its composition and related structures. In this study, we examined the effect of thrombin, which is engaged with fibrin, on osteoblast differentiation and its mode of action. Fibrin matrices were prepared with different concentrations of thrombin, and MC3T3-E1 pre-osteoblasts were cultured on the fibrin matrices. Thrombin-promoted fibrin-enhanced osteoblast differentiation in a dose-dependent manner, as confirmed by the extent of calcium deposition, alkaline phosphatase activity, and the level of Runx2. The synthetic activating peptide of protease-activated receptor 1 (PAR1), a prototype receptor of thrombin in osteoblast, did not alter the level of Runx2. Instead, the thrombin that was engaged with fibrin in a dose-dependent manner increased the phosphorylation of integrins β1 and β3. The integrin-blocking peptide RGDS reduced the thrombin-enhanced Runx2 in the cells grown on fibrin, whereas the non-functional peptide RGES did not change the level of Runx2. Furthermore, thrombin dose-dependently increased the fibronectin-binding of fibrin. The thrombin-induced integrin phosphorylation and Runx2 expression were also attenuated through the use of a blocking peptide to inhibit the binding of fibronectin to fibrin. The results in this study provide evidence that thrombin engaged with fibrin accelerates osteoblast differentiation via integrins but not PAR1 by modulating the fibronectin-binding capacity of fibrin. Crown Copyright Â
© 2012. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386921     DOI: 10.1016/j.biomaterials.2012.02.028

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  A bioengineered peripheral nerve construct using aligned peptide amphiphile nanofibers.

Authors:  Andrew Li; Akishige Hokugo; Anisa Yalom; Eric J Berns; Nicholas Stephanopoulos; Mark T McClendon; Luis A Segovia; Igor Spigelman; Samuel I Stupp; Reza Jarrahy
Journal:  Biomaterials       Date:  2014-07-23       Impact factor: 12.479

2.  Comparative evaluation of the biological properties of fibrin for bone regeneration.

Authors:  Joung-Hwan Oh; Hye-Jin Kim; Tae-Il Kim; Kyung Mi Woo
Journal:  BMB Rep       Date:  2014-02       Impact factor: 4.778

3.  Fibrin-Enhanced Canonical Wnt Signaling Directs Plasminogen Expression in Cementoblasts.

Authors:  Saeed Ur Rahman; Chan Ho Park; Jeong-Hwa Baek; Hyun-Mo Ryoo; Kyung Mi Woo
Journal:  Int J Mol Sci       Date:  2017-11-09       Impact factor: 5.923

4.  Reducing relapse and accelerating osteogenesis in rapid maxillary expansion using an injectable mesoporous bioactive glass/fibrin glue composite hydrogel.

Authors:  Hanjiang Zhao; Xiangyu Wang; Anting Jin; Minjiao Wang; Zeying Wang; Xingtai Huang; Jiewen Dai; Xudong Wang; Dan Lin; Steve Gf Shen
Journal:  Bioact Mater       Date:  2022-03-30

Review 5.  Zn-containing Adhesives Facilitate Collagen Protection and Remineralization at the Resin-Dentin Interface: A Narrative Review.

Authors:  Manuel Toledano; Manuel Toledano-Osorio; Matthias Hannig; Álvaro Carrasco-Carmona; María T Osorio; Franklin García-Godoy; Inmaculada Cabello; Raquel Osorio
Journal:  Polymers (Basel)       Date:  2022-02-08       Impact factor: 4.329

Review 6.  A review of fibrin and fibrin composites for bone tissue engineering.

Authors:  Alireza Noori; Seyed Jamal Ashrafi; Roza Vaez-Ghaemi; Ashraf Hatamian-Zaremi; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2017-07-12

Review 7.  Fibrin as a Multipurpose Physiological Platform for Bone Tissue Engineering and Targeted Delivery of Bioactive Compounds.

Authors:  Bruno Bujoli; Jean-Claude Scimeca; Elise Verron
Journal:  Pharmaceutics       Date:  2019-10-28       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.